SCHEMBL4832908

SCHEMBL4832908

Fc1ccc(B(Oc2cccc3cccnc23)c2ccc(Cl)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.51
NPC1 O15118 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
LMNA P02545 6/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
GAA P10253 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MAPT P10636 4/20 0.43
HPGD P15428 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HTT P42858 3/20 0.43
GLRA3 O75311 1/20 0.42
KDM4E B2RXH2 5/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
NPSR1 Q6W5P4 3/20 0.40
POLB P06746 1/20 0.40
SLC40A1 Q9NP59 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169850 0.94 LMNA (0.51) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL4179653 0.93 RAB9A (0.57) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL5164459 0.92 RAB9A (0.44) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL1186836 0.91 RAB9A (0.43) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL5166506 0.90 RAB9A (0.47) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL5163140 0.88 RAB9A (0.42) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL19849387 0.86 KMT2A (0.51) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL1188584 0.86 LMNA (0.44) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL5164821 0.85 LMNA (0.39) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL5167738 0.85 LMNA (0.42) RAB9ANPC1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7393856-B2 Anti-viral uses of borinic acid complexes ANACOR PHARMACEUTICALS, INC. (US) 2008-07-01 US disclosed
EP-1771182-A1 ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES Anacor Pharmaceuticals, Inc. (US) 2007-04-11 EP disclosed
EP-1765360-A2 ANTI-VIRAL USES OF BORINIC ACID COMPLEXES Anacor Pharmaceuticals, Inc. (US) 2007-03-28 EP disclosed
WO-2006085932-A2 ANTI-VIRAL USES OF BORINIC ACID COMPLEXES ANACOR PHARMACEUTICALS, INC. (US) 2006-08-17 WO disclosed
US-20060019927-A1 Anti-viral uses of borinic acid complexes ANACOR PHARMACEUTICALS, INC. 2006-01-26 US disclosed
US-20060014723-A1 Anti-parasitic uses of borinic acid complexes ANACOR PHARMACEUTICALS, INC. 2006-01-19 US disclosed
WO-2005123095-A1 ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES ANACOR PHARMACEUTICALS, INC. (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014723-A1 Anti-parasitic uses of borinic acid complexes BPGM, HRH1, HRH3 RAB9A 2635/4885NPC1 1480/4885MEN1 1345/4885
US-20060019927-A1 Anti-viral uses of borinic acid complexes SSB, BPGM, HAVCR2 RAB9A 3638/4885NPC1 1724/4885MEN1 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.